
06 February 2025
ANANDA PHARMA PLC
("Ananda" or the "Company")
Appointment of Commercial Adviser
Ananda Pharma plc (AQSE: ANA), a UK company focused on the development of cannabinoid therapies targeting the treatment of complex, chronic inflammatory pain conditions is pleased to announce the appointment of Andy Rust as a commercial adviser. Mr Rust will provide the Company with expert advice on its drug development and commercialisation plans.
Highlights:
· Mr Rust is a highly experienced pharmaceutical executive with direct experience marketing and selling licensed drugs in the US and in the pain sector
· Mr Rust has served as a senior commercial executive of several international pharmaceutical companies over a 30-year career
Mr Rust's most recent role was as Global Head of Respiratory with Chiesi Group, an international biopharmaceutical company which has a direct presence in 31 countries. At Chiesi, Mr Rust led the strategic direction and execution of the group's respiratory portfolio, which included products for asthma and COPD, to significantly grow revenues for the company's respiratory range to in excess of €1.5 billion.
Ananda's CEO, Melissa Sturgess commented: "We are delighted to have Andy join us as a commercial adviser. In our determination to bring cannabinoid drugs to market, including two forthcoming NHS sponsored phase 3 clinical trials, we are ensuring we always have our focus on the prize, which means understanding the marketing and sales ramifications of all our decisions along the way."
About Ananda Pharma
Ananda Pharma (AQSE: ANA), is a UK-based developer of licenced, CBD-based medicinal products. Ananda is developing a range of cannabinoid-based medicines targeting the treatment of complex, chronic inflammatory pain conditions. The Company is led by successful entrepreneurs and a team of world-class scientists.
For more information, please visit: www.anandapharma.co.uk
To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:
· Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93
· Instagram: https://www.instagram.com/anandapharmaplc/
· LinkedIn: https://www.linkedin.com/company/anandapharma
· X: https://twitter.com/AnandaPlc
· Investor Meet Company: https://www.investormeetcompany.com/ananda-pharma-plc/register-investor
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
|
ANANDA PHARMA PLC |
+44 (0)7463 686 497 |
|
|
|
|
Chief Executive Officer |
|
|
Melissa Sturgess |
|
|
|
|
|
Finance Director |
|
|
Jeremy Sturgess-Smith |
|
|
|
|
|
SP ANGEL CORPORATE FINANCE LLP |
+44 (0)20 3470 0470 |
|
|
|
|
Corporate Finance |
|
|
Richard Morrison |
|
|
|
|
|
|
|
|
Corporate Broking |
|
|
Abigail Wayne |
|
|
Rob Rees
|
|
|
Yellow Jersey PR (media enquiries) Sarah MacLeod Charles Goodwin Zara McKinlay |
+44 (0)20 3004 9512 ananda@yellowjerseypr.com |
https://investors.anandapharma.co.uk/link/MrDQpP